

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 25 avril 2023 16:00

Laboratory Information

Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Foot and mouth disease
Address of laboratory:	TALCAHUANO 1660, MARTINEZ, BUENOS AIRES ARGENTINA, CP 1640
Tel.:	+54 9 11 8746700
E-mail address:	SGALDO@SENASA.GOV.AR
Website:	https://www.argentina.gob.ar/senasa/laboratorios
Name (including Title) of Head of Laboratory (Responsible Official):	ANA MARIA NICOLA, DVM MSc DIRECTORA GENERAL DE LABORATORIO Y CONTROL TECNICO, DGLYCT, SENASA
Name (including Title and Position) of WOAHO Reference Expert:	SABRINA GALDO NOVO, DVM, PhD, Head of FMDV Diagnosis Department nbs 4 woah laboratory for FMDV, DLA, DGLYCT, SENASA
Which of the following defines your laboratory? Check all that apply:	Other: International Organization/ PANAFTOSA-PAHO/WHO Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
3 ABC ELISA / EITB	YES	14086	450
VIAA	YES	361	
LP ELISA	YES	9851	

VTN TEST FOR AB TITER DETERMINATION	YES	4308	
r1 value for vaccine matching assessment	YES	12	
Direct diagnostic tests		Nationally	Internationally
SUSPEC CASE FOR Q RT PCR DETECTION AND VIRAL ISOLATION	YES	7 CASES (20 SAMPLES TOTAL)	
VP1 SEQUENCING	YES	21	

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
GUINEA PIG COMPLEMENT	COMPLEMENT FIXATION TEST	362 ML / PROVIDED TO OTHER LABORATORIES 130 ML	130 ML	0 ML	0	America
RABBIT HEMOLISINE	COMPLEMENT FIXATION TEST FOR FA	160 ML	0	10 ML	1	America
GUINEA PIG HYPERIMMUNE SERA OF DIFFERENT FMDV STRAINS	FOR COMPLEMENT FIZATION TEST AND AS SERA OF REFERENCE	289 ML	0	20 ML	1	America
INACTIVATED VIRAL ANTIGENS FOR FMDV	FOR VACCINE CONTROL AND OTHER VIRAL YIELD STUDIES	29800 ML	0	0	0	
FMDV VIRUS SUSPENSION FOR CEPARIUM MANTAINANCEC	PD50 TESTS, PGP TEST, VIRUSNEUTRALIZATION TEST, VACCINE STUDIES, GENETIC CHARACTERIZATION AND ANTIGENIC CHARACTERIZATION	2535 LM	0	0	0	
POSITIVE SERA CONTROLS	FOR COMPLEMENT FIXATION AND VIRUSNEUTRALIZATION	40 ML	0	0	0	
EPITHELIA AND VESICULAR LIQUID STOCKS	PD50 TEST AND PGP TESTS	105 ML	0	0	0	

PANELS OF SERA	VIRUSNEUTRALIZATION TEST	304 ML	0	0	0	
----------------	-----------------------------	--------	---	---	---	--

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA H Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA H Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA H Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA H Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOA H MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Understanding cross-reactive responses between heterologous FMD virus strains in the bovine model	1 year	The main objective of this project is to carry out a rational study of heterologous protection between FMDV strains from the host (immune responses) and pathogen (antigenic determinants) perspectives.	INTA / USDA	ARGENTINA
FMDV circulating strains characterization in	renewal pending	antigenic characterization and vaccine matching cross protection	DAH VietnaM	VIETNAM

Vietnam	assessment of circulating strains in Vietnam	
---------	--	--

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

The analysis is always represented in a report to WOAHA annually.

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

article under review

b) International conferences:

2

- *OIE FMD Laboratory activities during 2022, SENASA, Argentina. OIE/FAO FMD Laboratory Network Meeting 29-30 Noviembre y 01 Diciembre 2022.*

- *Protective capacity of vaccines containing o1 campos a24 cruzeiro and a2001 argentina vaccine strains against fmd viral lineages. C. Caldevilla, J. Filippi, S. Galdo Novo, A. Taffarel, A. Ham, G. Balardon, J. Rodriguez Persico, J. Memebrebe, R. Scian, S. Cardillo. EuFMD OS2022. 26, 27, 28 October 2022 - Hybrid event / Marseille (France)*

c) National conferences:

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

Yes

a) Technical visit : 0

b) Seminars : 5

c) Hands-on training courses: 1

d) Internships (>1 month) 1

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
B	ARGENTINA	50
B	ARGENTINA	2
B	QATAR (3 seminars)	10
C	ARGENTINA	2
D	ARGENTINA	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	PDF	Certificado_de_acreditación.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA 3ABC	ORGANISMO ARGENTINO DE ACREDITACION - ARGENTINA

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

A Biosecurity commission and biosecurity specialists in an individual technical department is guaranteed. A technical service department is also responsible for technical requisites. SOP's are elaborated and all the employees comply with the requirements according to ISO 17025 and following international standard recommendations.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA H?

Yes

	Date		Role (speaker, presenting poster,	Title of the work
--	------	--	-----------------------------------	-------------------

Title of event	(mm/yy)	Location	short communications)	presented
17th Annual Meeting OIE/FAO Reference Laboratories	2022-11-29	Lelystad, the Netherlands and online	Speaker	Laboratory SENASA - Annual Report 2022
GFRA Gap analysis	2022-12-05	Buenos Aires, Argentina	Audience Presenting initial results of INTA/SENASA collaboration	Understanding cross- reactive responses between heterologous FMD virus strains in the bovine model

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

Not applicable (Only WOAHP Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

No

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report: